[SEN]SK Basa, which has few circulating stocks, goes beyond’Dad Sang’ to’Dad Sang’

[서울경제TV=김혜영기자] SK Bioscience, which has collected a margin of 64 trillion won, and has written a new history in the public offering stock market, will be listed on the 18th. One day ahead of the listing, interest is focused on how far the subscription momentum can lead. Securities prices are also open to the possibility of “tasangsang” beyond the so-called ‘dasang’ in which the public offering price doubled and went directly to the high-end price.

In the case of Kakao Games, which was regarded as the main word of the public offering stock market last year, it recorded an upper limit for two consecutive trading days after listing, and SK Biopharm recorded an upper limit for three consecutive trading days.

In the case of SK Bioscience, it surpassed the margins of Kakao Games and SK Biopharmaceuticals and succeeded in winning a box office, and it is evaluated that the stock has ample upside potential as the number of shares in circulation is smaller than that of the two companies.

A look at SK Bioscience’s securities issuance performance report shows that the amount of mandatory holdings promised has been higher than that of the initial demand forecast. Commitment to hold obligations means that the allocated public offering stocks are not sold for a certain period of time.

Of the national pension and other institutional allocations (12.622,500 shares), 85.26% is in the state of obligatory retention commitment for a minimum of 15 days to a maximum of 6 months. In other words, 85% of SK Bioscience’s public offering stocks cannot be sold on the day of listing. After entering the stock market, the volume of SK Bioscience that can be released to the market is expected to be only 8.87 million shares, or 11.5% of the total, except for the amount of large shareholders and institutions obligated to hold.

Earlier, the ratio of SK Biopharm’s mandatory retention commitment was 52.3%, and Kakao Games 72.6%. As such, SK Bioscience has much lower distribution available than the two companies. According to the law of supply and demand, demand is expected to be higher than on the day of listing, but expectations are rising for’Dad Sang’ beyond’Dad Sang’.

SK Bioscience, which starts trading in the securities market at 9 am on the 18th, will have an initial price in the range of 90 to 200% of the public offering price through the quotes formed at 8:30 am to 9:00 am on the same day. As SK Bioscience’s public offering price is 65,000 won, the initial price is expected to be set at 58,500 won to 130,000 won.

If SK Bioscience’s initial price is decided at 130,000 won, which is twice the public offering price, and soared to the upper limit, it could go up to 169,000 won. In this case, SK Bioscience’s market capitalization is expected to reach 12.900 trillion won.

Researcher Byung-Hwa Han said, “SK Bioscience has been selected as a vaccine development and production business for COVAX, a vaccine joint purchase consortium, and has prepared an opportunity to leap to a global vaccine company. -19 It is expected to change drastically according to the development and commercialization of vaccines.” “It is difficult to find comparable companies, but we believe that Curevec, Novavex, and BioEntech, which have grown rapidly due to COVID-19, will be the role models of the company’s value. If the phase 2 and 3 data of the self-developed COVID-19 vaccine are good enough to be released in the second half of next year, the stock will form at the level of the market cap of the global new vaccine companies mentioned above.”/[email protected]

/ Kim Hye-young [email protected]

< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >